anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Multiparameter flow cytometry is widely used for acute myeloid leukemia minimal residual disease testing (AML MRD) but is time consuming and demands substantial expertise. Machine learning offers potential advancements in accuracy and efficiency, but has yet to be widely adopted for this application. To explore this, we trained single cell XGBoost classifiers from 98 diagnostic AML cell populations and 30 MRD negative samples. Performance was assessed by cross-validation. Predictions were integrated with UMAP as a heatmap parameter for an augmented/interactive AML MRD analysis framework, which was benchmarked against traditional MRD analysis for 25 test cases. The results showed that XGBoost achieved a median AUC of 0.97, effectively distinguishing diverse AML cell populations from normal cells. When integrated with UMAP, the classifiers highlighted MRD populations against the background of normal events. Our pipeline, MAGIC-DR, incorporated classifier predictions and UMAP into flow cytometry standard (FCS) files. This enabled a human-in-the-loop machine learning guided MRD workflow. Validation against conventional analysis for 25 MRD samples showed 100% concordance in myeloid blast detection, with MAGIC-DR also identifying several immature monocytic populations not readily found by conventional analysis. In conclusion, Integrating a supervised classifier with unsupervised dimension reduction offers a robust method for AML MRD analysis that can be seamlessly integrated into conventional workflows. Our approach can support and augment human analysis by highlighting abnormal populations that can be gated on for quantification and further assessment. This has the potential to speed up MRD analysis, and potentially improve detection sensitivity for certain AML immunophenotypes.
BACKGROUND: Acute pancreatitis (AP) is an inflammatory condition with potentially life-threatening complications. This study investigates the therapeutic potential of Clostridium butyricum for modulating the inflammatory cascade through the AMPK/NF-κB signaling pathway, focusing on inflammation induced by AP. LC-MS analysis of serum samples from AP patients highlighted the regulation of lipid metabolism and inflammation, and found that metabolites involved in the inhibition of NF-κB phosphorylation and the AMPK activation pathway were downregulated. We hypothesized that pre-administration of Clostridium butyricum and its culture supernatant could mitigate AP-induced damage by modulating the AMPK/NF-κB pathway.
METHODS: Lipopolysaccharide (LPS)-induced cell inflammation models. LPS combined with CAE induced acute pancreatitis in mice. We divided mice into four groups: Con, AP, AP + C.Buty (AP with Clostridium butyricum treatment), and AP + CFS (AP with culture supernatant treatment). Analyses were performed using WB, RT-qPCR, Elisa, flow cytometry, IHC, and HE, respectively.
RESULTS: Our study shows that CFS can reduce the apoptosis of LPS-induced cellular inflammation and reduce the release of LPS-induced cytoinflammatory factors through the AMPK/NF-κB pathway in vitro. In vivo, Clostridium butyricum and its supernatant significantly reduced inflammatory markers, and corrected histopathological alterations in AP mice. Gut microbiota analysis further supported these results, showing that Clostridium butyricum and its supernatant could restore the balance of intestinal flora disrupted by AP.
CONCLUSIONS: Mechanistically, our results indicated that the therapeutic effects of Clostridium butyricum are mediated through the activation of AMPK, leading to the inhibition of the NF-κB pathway, thereby reducing the production of pro-inflammatory cytokines. Clostridium butyricum and its culture supernatant exert a protective effect against AP-induced damage by modulating the AMPK/NF-κB signaling pathway. Future studies will further elucidate the molecular mechanisms underlying the beneficial effects of Clostridium butyricum in AP and explore its clinical applicability in human subjects.
An intelligent gait analyzing apparatus comprises a first camera and an electronic device. The first camera captures a first video in which the patient walks and a second video in which the patient changes a posture from standing up to sitting down. A second camera may be used to capture a three-dimensional point cloud diagram of the patient to generate a chest skeleton and an abdomen skeleton. A 3D skeleton model and a moving diagram may be created based on the first video. The memory stores a long short-term memory model, a transformer machine learning model and an algorithm of modified gravity center. The graphic processor calculates a gravity center deviation based on the moving diagram, the chest skeleton and the abdomen skeleton. The graphic processor acquires a stride, a pace, a humpbacked value and a risk of falling.
Study subjects will receive 18FDG via an IV before undergoing one PET/CT scan over 60 minutes. They will then receive an IV injection of Gadovist for contrast before undergoing a multiparametric MRI scan. Subjects will also receive (18)F-FDOPA via an IV before undergoing another PET/CT scan over 60 minutes.
1,256,092. Antiviral preparations. UPJOHN CO. 9 March, 1970 [12 Dec., 1968], No. 27978/ 68. Headings A5B and ASE.  Antiviral preparations consist of an active ingredient selected from elenolic acid, elenolide, alkali metal and alkaline earth metal salts of elenolic acid, iron, zinc and ammonium elenolate, C 1-6  alkyl ethers of elenolic acid, C 1-6  alkyl ether esters of elenolic acid, and C 1-6  alkyl esters of elenolic acid and (a) a compatible buffer salt adapted to provide in solution a pH of 6.3 to 6.7, the preparation being in the form a freeze-dried solid; or (b) a compatible liquid vehicle, and a compatible buffer salt and being in the form of a liquid preparation of pH 6.3 to 6.7; or (c) being suspended in a liquid normally gaseous propellant and adapted to form an aerosol. The preparations are used in the treatment of polio, influenza, herpes, Newcastle disease, rabies, EMC and other respiratory infections and may be administered nasally in the form of sprays, mists, nebulae and aerosols. The antiviral preparations are also used for decontaminating surgical instruments or eating utensils, washing walls, purifying water and in air purification systems.
Participants in this group will apply a 45-minute training program at home, consisting of 5 minutes of Ujjayi pranayama, 5 minutes of Nadi-Shodhana pranayama and 5 minutes of Sukha pranayama, 7 days a week for 8 weeks, 3 times a day. In addition, they will perform a 15-minute session 3 day a week for 8 weeks, under the online supervision of a physiotherapist. The training program will last 8 weeks.
Prodn. of intestinally resorbable protein and peptide solns. from extracts of biological tissues including proteinaceous hormones and insulin, comprises introducing aq. solns. of the tissues in liposomes or in a water-in-oil emulsion, for application in medicament capsules which dissolve in the small intestine. The process may be used for other intestinally inactive medicaments and inoculants, partic. glycoproteides, heteroglycanes, polysaccharides, immunoglobulins, cardiac glycosides, etC.
Promethazine VC with Codeine Oral Solution contains codeine, a Schedule V controlled substance. As an opioid, Promethazine VC with Codeine Oral Solution exposes users to the risks of addiction, abuse, and misuse [ see Drug Abuse and Dependence ( 9)], which can lead to overdose and death [ see Overdosage ( 10)]. Reserve Promethazine VC with Codeine Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. Assess each patient’s risk prior to prescribing Promethazine VC with Codeine Oral Solution, prescribe Promethazine VC with Codeine Oral Solution for the shortest duration that is consistent with individual patient treatment goals, monitor all patients regularly for the development of addiction or abuse, and refill only after reevaluation of the need for continued treatment.

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Promethazine VC with Codeine Oral Solution. Addiction can occur at recommended dosages and if the drug is misused or abused. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (eg., major depression).

Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing Promethazine VC with Codeine Oral Solution. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [see Patient Counseling Information (17)]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
Breast cancer remains a leading cause of cancer mortality in women globally. Despite advancements in systemic therapy, the risk of distant recurrence persists even after such treatment and may be linked to disseminated tumor cells (DTCs). Variability in molecular characteristics between primary tumors (PTs) and distant metastases underscores the need to comprehensively understand metastatic pathways. This retrospective study investigated discrepancies between HER2 expression in PTs and DTCs and their implications for survival outcomes in 201 early breast cancer (EBC) patients. We found a significant association between HER2 expression in PTs and DTCs when classifying tumors as HER2-high/low/negative. Patients whose HER2 status was discordant between PTs and DTCs exhibited worse distant disease-free survival than those with concordant status. Multivariate analysis confirmed the HER2 status of DTCs as an independent prognostic factor for distant DFS. These findings emphasize the importance of assessing HER2 expression in DTCs and its potential implications for tailored therapy strategies in EBC. Furthermore, prospective trials are needed to validate these findings and explore targeted therapies based on the molecular characteristics of DTCs.
Partial sleep restriction (PSR) followed by total sleep deprivation (TSD). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
Vasculogenic mimicry (VM) is a novel model for supplying blood to multiple tumors, including gastric cancer (GC), and is a potential target for its treatment. Dihydroartemisinin (DHA) is a potential natural antitumor substance that inhibits the progression of tumors in many ways. The research aimed to evaluate the impact of DHA on VM formation and its mechanisms. The IC50 of DHA, DHA's effect on proliferation, invasion, and migration in GC cells and VM formation in both cell and animal models were determined through wound healing, MTT, EdU, colony formation, and Transwell assays. Genomics was employed to identify genes related to DHA inhibition of VM formation, and to analyze their relationship to VM formation. qRT‒PCR and western blot (WB) analysis were carried out to analyze the changes in protein and mRNA levels after DHA treatment and the changes in VM-associated protein biomarkers after blocking target gene-related pathways. The mechanism by which DHA inhibits VM in GC was elucidated in vivo. DHA reduced the invasion, proliferation, and migration of GC cells and inhibited VM in cells and in vivo. A total of 220 DEGs were identified in the DHA-treated HGC-27 cells. Among the 146 downregulated genes, fibroblast growth Factor 2 (FGF2) was most closely associated with angiogenesis and VM. The level of FGF2 in GC tissues with VM was markedly greater than in VM lacking tissues. Treatment with DHA or FGFR1 blockade suppressed VM formation and reduced VM-related biomarker proteins. DHA suppressed tumor progression and VM formation by reducing FGF2 in xenograft mouse models. Per our knowledge, this is the first study to demonstrate the inhibitory effect of DHA on VM, providing a novel strategy for the treatment of GC.
The Group 2 will be randomized to the standard of care. Standard of care will be left to the discretion of the sites (clusters) participating in the study.
Consumption of sugar-sweetened beverages (SSB) is considered as an important risk factor for the development of overweight and obesity in populations worldwide, with a particular focus on the risks in the younger parts of the population - children and adolescents. Together with fiscal measures and information tools, innovation-based approaches such as the development of sugar-free or sugar-reduced versions of established beverages and development of new beverage products have been used to reduce this challenge, but the effects of product innovation on sugar intake are not well understood from the literature, as previous studies have largely ignored substitution effects of product innovation in the beverage domain. The objective of the present study was to investigate the potential effectiveness of product innovation as a strategy to affect consumers' intake of energy from sweetened non-alcoholic beverages. Using household panel shopping data from approximately 3000 Danish households over the years 2006-2014, we developed a hedonic pricing approach to estimate the influence of product attributes on consumers' utility, based on observed data for Danish households' purchases of sweet drinks. Overall, the study found that beverages' degree of sweetness positively affected the satiation effect of beverage consumption and in turn made the demand for these beverages less sensitive to e.g. price changes or introduction of competing products, whereas the energy density of the beverages positively affected the demand sensitivity to market changes. Findings like these can be useful for assessing market effects as well as environmental and public health impacts of changes to the market environment.
The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planing under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
Fifty-six obese, drug naive patients with type 2 diabetes mellitus were enrolled and completed the study. Twenty-six healthy subjects matched for age and body mass index (BMI) served as nondiabetic controls. All subjects were postmenopausal women with last menses at least 2 years. After the baseline measurements, all subjects were instructed to follow a weight-maintaining diet, based on ADA recommendations, and were also encouraged to walk or to jog at least 30 min daily. Subsequently, 28 of the diabetic subjects were randomly assigned to receive rosiglitazone (4 mg/day). Twenty-eight of diabetic subjects were on diet alone. The randomization procedure was based on a random sequence.

All subjects had a complete clinical examination, anthropometric measurements, and laboratory tests at baseline and at the end of the 12th week of the study. Laboratory investigations included assessment of: (i) glycemic control (HbA1c, fasting plasma glucose and insulin levels, and homeostasis model assessment (HOMA) index (22); (ii) serum bsALP and active human osteocalcin concentration (OCL) as markers of bone formation; (iii) urine deoxypyridinoline (DPD) as marker of bone resorption. Other non-specific bone markers including serum total ALP activity, urinary calcium (Ca) and phosphate (PO4) concentrations were also measured. Urine concentrations of DPD (nmol/L), Ca and PO4 (both in mmol/L) were corrected for their respective urine creatinine (Cr) concentrations in mmol/L (Urine DPD/Cr, Urine Ca/Cr and Urine PO4/Cr respectively). In addition, fasting blood samples were analyzed for plasma cytokine levels including IL-1β, IL-6 and TNF-α, and for haptoglobin levels.
The patients will receive Korean red ginseng(Korean Red Ginseng Powder Capsule®; Korea Ginseng Corporation, Daejeon, Korea). Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
Machine Learning (ML): Approximately 200 paired WB-MRI scans from 100 patients (scanned at baseline with active disease and then post treatment) will be used to develop a machine learning tool to quantify the burden of disease. The machine learning algorithm will then be tested on a further additional set of 60 patients who previously had two WB-MRI scans comprising paired baseline (with active disease) and post treatment scans. The agreement of radiology readers to evaluate the burden of disease will be measured against the reference standard (expert panel) with and without machine learning support.
Cladribine 5mg/m2 in 2 h i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after cladribine infusion on days (1-5) Mitoxantrone 10 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
<P>PROBLEM TO BE SOLVED: To provide a gommage cosmetic for removing keratotic plug, which can also remove lipid in a portion where keratotic plug is present.  <P>SOLUTION: (1) 5-20 mass% polyvinyl acetate emulsion in terms of a solid content, and (2) 20-40 mass% hydrocarbon which is liquid at 1 atm and 25°C are incorporated in a cosmetic in the form of an oil-in-water emulsion. Preferably, the cosmetic further contains 1-5 mass% dipropylene glycol and/or 1-5 mass% diester of a dibasic acid. The cosmetic is applied in an adequate amount to the skin by repetitive massage to carry out gommage thereby removing keratotic plug. An effect as a massage cosmetic is also provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
In the intervention arm, demand creation for couples' HCT is done using small group (comprising about 20 people), couple-focused or men-only, interactive sessions. A senior counselor facilitates the sessions in which the advantages and fears associated with couples' HCT are discussed with invited couples or men. The sessions are reinforced by testimonies from couples or men who have ever tested as a couple. Attending couples or men receive couple invitation coupons inviting them to test for HIV together with their partners at a designated health facility in the community.
This is an open-label (physician and participant will know the name of the assigned drug), multi-center, non-randomized, drug/drug interaction study of JNJ-38518168 in participants with rheumatoid arthritis (RA) on a stable oral methotrexate (MTX) dose (7.5-25 mg). The treatment phase will last 16 days. Participants will be housed in the clinic for dosing and study procedures from Day -1 to Day 2 and again from Day 14 to Day 16. Participants completing treatment will have a follow-up visit between Days 22 and 25. Participants who discontinue the study prematurely will complete the Day 22 to 25 follow-up procedures at the time of discontinuation or as soon as possible thereafter. The duration of participation in the study for an individual participant will be up to 7 weeks (including screening). Participant safety will be monitored. Day 1: A single oral dose of the participant's weekly methotrexate dose. Days 2-15: Weekly MTX co-administered with two 50-mg capsules of JNJ-38518168, administered daily.
<P>PROBLEM TO BE SOLVED: To provide a method and an apparatus for cryoprecipitation and chromatography.  <P>SOLUTION: A method and a system 10 for selectively removing one component of a material thereby concentrating other components of the material are disclosed. The material is cooled to below the melting temperature of the material to form a supercooled liquid phase with heat transfer plate with cooling channels 20. Ultrasonic energy from ultrasonic drivers 42 is applied to the material to form solid phase crystals of the component to be removed. These crystals are removed to leave the concentrated product. The ultrasonic energy prevents the growth of dendrite on the crystals to remove small crystals of the component to be removed without damage to or removal of the remaining components.  <P>COPYRIGHT: (C)2009,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a nail cleansing agent capable of sufficiently removing stain such as yellowing of nail without being accompanied with unpleasant odor by making the agent include sodium oxalate. SOLUTION: This nail-cleansing agent contains sodium oxalate. Preferably, the nail-cleansing agent is obtained by dissolving sodium oxalate in water or hot water and formulating sodium oxalate so as to have 0.05-5.0 g/L concentration whenever it is used and as necessary, further, formulating 1-20 wt.% humectant (e.g. glycerol, castor oil or sodium polyacrylate), 0.01-5 wt.% enzyme (e.g. protease) and 0.01-10 wt.% surfactant (e.g. sodium lauryl sulfate) therewith.
The invention relates to a 2-phenyl naphthalene derivative, a preparation method and application thereof. The 2-phenyl naphthalene derivatives are FL-2 and FL-3. The invention also provides a preparation method of the 2-phenyl naphthalene derivatives FL-2 and FL-3, and application of the 2-phenyl naphthalene derivatives in preparing topoisomerase II catalytic inhibitors and antitumor drugs. The invention reports the application of the 2-phenyl naphthalene derivative in preparing TopoII alpha catalytic inhibitor for the first time. The 2-phenyl naphthalene derivatives FL-2 and FL-3 provided by the invention have strong topoisomerase II inhibition activity and show a certain topoisomerase II alpha subtype selectivity. At the cellular level, the proliferation of tumor cells can be obviously inhibited by inhibiting the expression of the topoisomerase II, and the topoisomerase II can be used as a catalytic inhibitor for the development of antitumor drugs.
BACKGROUND: In patients with schizophrenia, violent behavior is a clinically important factor that prevents their discharge. Clozapine is an effective antipsychotic medication for treatment-resistant schizophrenia, and its usefulness for aggressive behavior has also been suggested.
CASE PRESENTATION: We present the case of a 38-year-old male patient diagnosed with schizophrenia who was successfully treated with clozapine after recurrent violent behavior. He was diagnosed with schizophrenia during his adolescence. He was hospitalized for treatment in his teens, but his hallucinations and delusions persisted even after discharge. In his 30s, he became noticeably emotionally unstable, and despite being treated for an adequate period with sufficient doses of several antipsychotics, his symptoms did not improve. This led to repeated hospitalizations triggered by violent behavior toward his parents and siblings within the home. During his fourth hospitalization, clozapine was initiated due to multiple incidents of violence toward nursing staff secondary to hallucinations and delusions. As the dose of clozapine was gradually increased with therapeutic drug monitoring, the patient's hostility, uncooperativeness, and suspiciousness markedly improved, and his aggressive behavior disappeared. He was discharged to a facility on day 194 after starting clozapine and has continued outpatient visits.
CONCLUSION: Clozapine was suggested to be effective for aggressive behavior in patients with treatment-resistant schizophrenia and should be actively considered. In such cases, regular measurement of blood concentration is useful for adjusting the dosage of clozapine.